These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26414905)

  • 41. Telaprevir: changing the standard of care of chronic hepatitis C.
    Rajani AK; Ravindra BK; Dkhar SA
    J Postgrad Med; 2013; 59(1):42-7. PubMed ID: 23525057
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience.
    Ikegami T; Ueda Y; Akamatsu N; Ishiyama K; Goto R; Soyama A; Kuramitsu K; Honda M; Shinoda M; Yoshizumi T; Okajima H; Kitagawa Y; Inomata Y; Ku Y; Eguchi S; Taketomi A; Ohdan H; Kokudo N; Shimada M; Yanaga K; Furukawa H; Uemoto S; Maehara Y
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28881052
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
    Hassanein T; Sims KD; Bennett M; Gitlin N; Lawitz E; Nguyen T; Webster L; Younossi Z; Schwartz H; Thuluvath PJ; Zhou H; Rege B; McPhee F; Zhou N; Wind-Rotolo M; Chung E; Griffies A; Grasela DM; Gardiner DF
    J Hepatol; 2015 May; 62(5):1204-6. PubMed ID: 25559328
    [No Abstract]   [Full Text] [Related]  

  • 44. [Interferon-free treatment for patients with chronic hepatitis C].
    Suzuki F
    Nihon Rinsho; 2015 Feb; 73(2):285-91. PubMed ID: 25764684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
    Akuta N; Sezaki H; Suzuki F; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2016 Mar; 88(3):506-11. PubMed ID: 26292191
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
    Suda G; Kudo M; Nagasaka A; Furuya K; Yamamoto Y; Kobayashi T; Shinada K; Tateyama M; Konno J; Tsukuda Y; Yamasaki K; Kimura M; Umemura M; Izumi T; Tsunematsu S; Sato F; Terashita K; Nakai M; Horimoto H; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    J Gastroenterol; 2016 Jul; 51(7):733-40. PubMed ID: 26768604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
    Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
    J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.
    Ishigami M; Hayashi K; Honda T; Kuzuya T; Ishizu Y; Ishikawa T; Nakano I; Urano F; Kumada T; Yoshioka K; Goto H; Hirooka Y
    J Gastroenterol Hepatol; 2017 Nov; 32(11):1879-1886. PubMed ID: 28258705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Nishimura D; Goto H; Hirooka Y
    Clin J Gastroenterol; 2016 Aug; 9(4):252-6. PubMed ID: 27329484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful treatment of post-transplant hepatitis C virus cirrhosis with daclatasvir and asunaprevir.
    Ozaras R; Mete B; Yemisen M; Balkan II; Alkan M; Tabak F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):393-4. PubMed ID: 26405716
    [No Abstract]   [Full Text] [Related]  

  • 52. [Combined therapy with daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b: a case report].
    Pi SN; Chen YP
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Aug; 36(8):1163-4. PubMed ID: 27578593
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
    Eley T; He B; Chang I; Colston E; Child M; Bedford W; Kandoussi H; Pasquinelli C; Marbury TC; Bertz RJ
    Antivir Ther; 2015; 20(1):29-37. PubMed ID: 24704773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells.
    de Ruiter PE; Boor PP; de Jonge J; Metselaar HJ; Tilanus HW; Ijzermans JN; Kwekkeboom J; van der Laan LJ
    Transpl Infect Dis; 2015 Oct; 17(5):707-15. PubMed ID: 26250892
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug-induced lung injury associated with combination therapy of daclatasvir and asunaprevir: The first case report.
    Kamada T; Furuta K; Tomioka H
    Respir Investig; 2016 May; 54(3):207-10. PubMed ID: 27108017
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals.
    Lee DH; Ryu SH; Myung HJ; Shin YJ; Lee SH; Park TY; Moon JS
    Korean J Gastroenterol; 2021 Feb; 77(2):88-91. PubMed ID: 33633000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmacological properties and clinical efficacy of daclatasvir (Daklinza®) and asunaprevir (Sunvepra®)].
    Amano M; Ishikawa H
    Nihon Yakurigaku Zasshi; 2015 Mar; 145(3):152-62. PubMed ID: 25765498
    [No Abstract]   [Full Text] [Related]  

  • 59. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
    McPhee F; Sheaffer AK; Friborg J; Hernandez D; Falk P; Zhai G; Levine S; Chaniewski S; Yu F; Barry D; Chen C; Lee MS; Mosure K; Sun LQ; Sinz M; Meanwell NA; Colonno RJ; Knipe J; Scola P
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5387-96. PubMed ID: 22869577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation.
    Lim YS; Nguyen LP; Lee GH; Lee SG; Lyoo KS; Kim B; Hwang SB
    Mol Cells; 2021 Sep; 44(9):688-695. PubMed ID: 34518443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.